Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity.

dc.contributor.author

Farooq, Faheem

dc.contributor.author

Mogayzel, Peter J

dc.contributor.author

Lanzkron, Sophie

dc.contributor.author

Haywood, Carlton

dc.contributor.author

Strouse, John J

dc.date.accessioned

2020-07-01T20:07:47Z

dc.date.available

2020-07-01T20:07:47Z

dc.date.issued

2020-03-02

dc.date.updated

2020-07-01T20:07:47Z

dc.description.abstract

Importance:Sickle cell disease (SCD) and cystic fibrosis (CF) are severe autosomal recessive disorders associated with intermittent disease exacerbations that require hospitalizations, progressive chronic organ injury, and substantial premature mortality. Research funding is a limited resource and may contribute to health care disparities, especially for rare diseases that disproportionally affect economically disadvantaged groups. Objective:To compare disease-specific funding between SCD and CF and the association between funding and research productivity. Design, Setting, and Participants:This cross-sectional study examined federal and foundation funding, publications indexed in PubMed, clinical trials registered in ClinicalTrials.gov, and new drug approvals from January 1, 2008, to December 31, 2018, in an estimated US population of approximately 90 000 individuals with SCD and approximately 30 000 individuals with CF. Main Outcomes and Measures:Federal and foundation funding, publications indexed in PubMed, clinical trial registrations, and new drug approvals. Results:From 2008 through 2018, federal funding was greater per person with CF compared with SCD (mean [SD], $2807 [$175] vs $812 [$147]; P < .001). Foundation expenditures were greater for CF than for SCD (mean [SD], $7690 [$3974] vs $102 [$13.7]; P < .001). Significantly more research articles (mean [SD], 1594 [225] vs 926 [157]; P < .001) and US Food and Drug Administration drug approvals (4 vs 1) were found for CF compared with SCD, but the total number of clinical trials was similar (mean [SD], 27.3 [6.9] vs 23.8 [6.3]; P = .22). Conclusions and Relevance:The findings show that disparities in funding between SCD and CF may be associated with decreased research productivity and novel drug development for SCD. Increased federal and foundation funding is needed for SCD and other diseases that disproportionately affect economically disadvantaged groups to address health care disparities.

dc.identifier

2763606

dc.identifier.issn

2574-3805

dc.identifier.issn

2574-3805

dc.identifier.uri

https://hdl.handle.net/10161/21139

dc.language

eng

dc.publisher

American Medical Association (AMA)

dc.relation.ispartof

JAMA network open

dc.relation.isversionof

10.1001/jamanetworkopen.2020.1737

dc.subject

Science & Technology

dc.subject

Life Sciences & Biomedicine

dc.subject

Medicine, General & Internal

dc.subject

General & Internal Medicine

dc.subject

HEALTH-CARE

dc.subject

BIOMEDICAL-RESEARCH

dc.subject

MORTALITY-RATES

dc.subject

GENE-THERAPY

dc.subject

PAIN CRISES

dc.subject

TRANSPLANTATION

dc.subject

IDENTIFICATION

dc.subject

IVACAFTOR

dc.subject

CHILDREN

dc.subject

SURVIVAL

dc.title

Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity.

dc.type

Journal article

duke.contributor.orcid

Strouse, John J|0000-0003-0341-1457

pubs.begin-page

e201737

pubs.issue

3

pubs.organisational-group

School of Medicine

pubs.organisational-group

Pediatrics, Hematology-Oncology

pubs.organisational-group

Medicine, Hematology

pubs.organisational-group

Duke

pubs.organisational-group

Pediatrics

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.publication-status

Published

pubs.volume

3

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Farooq SCD vs. CF Funding JAMA Open 20.pdf
Size:
933.5 KB
Format:
Adobe Portable Document Format